Pancreatic Cancer Research

ResearcherOspedale P. Pederzoli – Casa di Cura Privata S.p.a.Active in the last 2 years

Alessandro Giardino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7980-5781; OpenAlex author ID A5041627120. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 23

  1. Multicenter IGoMIPS Registry-based analysis of robotic versus laparoscopic approach to left pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s13304-026-02831-3↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2026.117352↗
  3. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Co-author DOI 10.3390/cancers18050830↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. Unconventional Treatments for Pancreatic Cancer: A Systematic Review. First author DOI 10.3390/cancers17091437↗
  6. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  7. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16234106↗
  8. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.02.005↗
  9. Telemedicine and Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1089/tmj.2022.0140↗
  10. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  11. CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients. First author DOI 10.3390/cells11213340↗
  12. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  13. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  14. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Regis… Co-author DOI 10.1038/s41395-018-0414-z↗
  15. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Lite… Co-author DOI 10.3390/cancers11070981↗
  16. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Co-author DOI 10.1007/s00423-017-1627-0↗
  17. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Co-author DOI 10.1007/s00464-018-6217-x↗
  18. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Co-author DOI 10.1016/j.pan.2017.09.008↗
  19. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Co-author DOI 10.1245/s10434-017-5885-4↗
  20. Role of local ablative techniques (Radiofrequency ablation and Irreversible Electroporation) in the treatment of pancreatic cancer. Co-author DOI 10.1007/s13304-016-0385-9↗
  21. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Co-author DOI 10.1155/2016/4508376↗
  22. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center. Co-author DOI 10.1007/s00534-013-0613-3↗
  23. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.8789↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabella M. Frigerio · 18 shared papers, 2012–2026 · strength 2.07
  2. Giovanni Butturini · 13 shared papers, 2017–2026 · strength 1.81
  3. Roberto Girelli · 14 shared papers, 2012–2026 · strength 1.38
  4. Paolo Regi · 10 shared papers, 2013–2026 · strength 1.15
  5. Filippo Scopelliti · 9 shared papers, 2017–2026 · strength 1.10
  6. Claudio Bassi · 11 shared papers, 2012–2022 · strength 0.76
  7. Erica Pizzocaro · 3 shared papers, 2023–2026 · strength 0.75
  8. Roberto Salvia · 9 shared papers, 2012–2022 · strength 0.64
  9. Roberta Vella · 2 shared papers, 2025–2026 · strength 0.53
  10. Salvatore Paiella · 7 shared papers, 2016–2021 · strength 0.50
  11. Giuseppe Malleo · 5 shared papers, 2017–2022 · strength 0.43
  12. Marzia Tripepi · 2 shared papers, 2023 · strength 0.38
  13. Mirko D’Onofrio · 5 shared papers, 2016–2021 · strength 0.36
  14. Gaya Spolverato · 2 shared papers, 2023–2024 · strength 0.35
  15. Quoc Riccardo Bao · 2 shared papers, 2023–2024 · strength 0.35
  16. Paolo Pederzoli · 2 shared papers, 2018–2026 · strength 0.33
  17. Alessandro Esposito · 2 shared papers, 2020–2022 · strength 0.21
  18. Matteo De Pastena · 2 shared papers, 2018–2022 · strength 0.20
  19. Darío Gregori · 1 shared paper, 2024 · strength 0.19
  20. Roberto Bianco · 2 shared papers, 2019–2021 · strength 0.18
  21. Michèle Milella · 2 shared papers, 2020–2021 · strength 0.17
  22. Giovanni Marchegiani · 2 shared papers, 2018–2020 · strength 0.14
  23. Paola Capelli · 2 shared papers, 2017–2020 · strength 0.13
  24. Stefania Scala · 1 shared paper, 2022 · strength 0.13
  25. Ferdinando De Vita · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.